AM-Pharma is focused on developing innovative treatments for severe medical conditions, particularly targeting cardiac surgery-associated renal damage (CSA-RD) and hypophosphatasia (HPP). Their proprietary compound, ilofotase alfa, is a recombinant alkaline phosphatase that has shown a strong safety profile and reno-protective effects in clinical trials involving over 1,000 subjects. The compound is being advanced into a Phase 2 study to evaluate its efficacy in preventing renal damage during cardiac surgeries, where acute kidney injury (AKI) is a significant risk. Additionally, ilofotase alfa is being explored as a potential enzyme replacement therapy for HPP, a rare genetic disorder that affects bone mineralization and can lead to severe complications.

Ilofotase alfa operates by dephosphorylating and detoxifying various damage-associated and pathogen-associated molecular patterns that contribute to inflammation and kidney injury. This mechanism not only helps in protecting renal function but also reduces inflammation through the activation of specific receptor pathways. The compound has received FDA fast-track status and orphan drug designation for its applications in both CSA-RD and HPP, underscoring its potential to address critical unmet medical needs in these patient populations. AM-Pharma's commitment to advancing ilofotase alfa reflects their dedication to improving the lives of patients facing severe health challenges.

Netherlands

AM–Pharma is a biopharmaceutical company developing proprietary recombinant human Alkaline Phosphatase (AP) therapeutics, which have the potential to transform the treatment prospects for patients with Acute Kidney Injury, Inflammatory Bowel Disease and Hypophosphatasia.

AM-Pharma

Company Details